Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
Najat Khan filed a Rule 144 notice to sell Common Stock of Recursion Pharmaceuticals. The filing lists intended sales dated 05/15/2026 of 18,422 shares and 7,788 shares described as Equity Compensation. The excerpt also reports a prior sale of 28,298 shares on 03/09/2026 for $94,662.47.
Christopher C. Gibson filed a Form 144 reporting a proposed sale of 40,000 Class A shares. The filing lists multiple sales of 40,000 Class A shares each during March–May 2026 with proceeds shown per trade.
Reported sales: 03/23/2026 $130,000; 04/07/2026 $124,000; 04/22/2026 $144,400; 05/07/2026 $134,800; 05/22/2026 $123,200.
RECURSION PHARMACEUTICALS director Namandje Bumpus sold shares in a pre-planned trade. On this Form 4, Bumpus reported an open-market sale of 4,386 shares of Class A common stock at an average price of $3.54 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After this transaction, Bumpus directly holds 43,171 shares of Recursion Pharmaceuticals, so the sale reflects only a portion of the director’s overall stake.
Recursion Pharmaceuticals director Blake Borgeson sold shares in a planned trade. On June 2, he executed an open-market sale of 30,000 shares of Class A Common Stock at $3.68 per share. After the sale, he directly holds 6,169,863 shares. The transaction was made under a Rule 10b5-1 trading plan adopted on August 31, 2025.
RXRX submitted a Form 144 notice describing proposed or reported sales of Class A shares. The filing lists multiple transactions by Blake C. Borgeson: 170,000 shares on 03/03/2026 for $588,200, 30,000 shares on 04/07/2026 for $93,000, and 30,000 shares on 05/05/2026 for $105,600. The excerpt also shows a 30,000-share allocation labeled as Founders Shares dated 09/19/2017 and an entry for Fidelity Brokerage Services LLC with 30,000 and $110,400.
RECURSION PHARMACEUTICALS director Christopher Gibson converted and sold shares in a planned set of transactions. On May 22, 2026, he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock, then sold those 40,000 Class A shares in an open-market transaction at $3.08 per share. The filing notes the activity was carried out under a Rule 10b5-1 trading plan adopted on May 12, 2025, indicating the trades were pre-scheduled. After these moves, he directly holds 883,735 Class A shares and 4,303,334 Class B shares, with each Class B share convertible into one Class A share.
RXRX discloses a Form 144 notice showing proposed sales of Class A shares totaling 40,000 shares via Fidelity Brokerage Services LLC. The filing also lists recent open-market sales by Christopher C. Gibson on 03/23/2026, 04/07/2026, 04/22/2026, and 05/07/2026, each for 40,000 shares with aggregate transaction amounts shown in the record.
Recursion Pharmaceuticals Chief Scientific Officer David Hallett reported a tax-related share disposition. On this Form 4, 26,657 shares of Class A Common Stock were withheld at a price of $3.04 per share to cover tax obligations tied to restricted stock units.
These shares were retained by the company to satisfy withholding and remittance duties in connection with net-settled RSUs, not sold on the open market. After this withholding event, Hallett directly holds 1,070,494 shares of Class A Common Stock.
RECURSION PHARMACEUTICALS, INC. CEO and President Najat Khan reported a routine tax-related share disposition. On this Form 4, 62,701 shares of Class A Common Stock were withheld at $3.04 per share to satisfy tax withholding and remittance obligations tied to the net settlement of restricted stock units, rather than being sold on the open market. Following this withholding, Khan directly holds 2,199,384 shares of Class A Common Stock.